Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Clinical Trial
Official title:
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
This is a Randomized, Double-Blind, Placebo-Controlled Study designed to assess safety, tolerability, and efficacy of NM8074 in AAV patients when used in combination with Standard of Care (SOC) cyclophosphamide/azathioprine or rituximab plus corticosteroids.
The proposed study, NM8074-AAV-501, will initially assign six (6) patients per cohort in a 2-cohort trial. In the first cohort, we will evaluate a biweekly dosing regimen with NM8074 and SOC whereas in the second cohort, we will evaluate placebo with SOC. These studies will assess safety, tolerability, and efficacy of NM8074 in AAV patients when used in combination with SOC cyclophosphamide/azathioprine or rituximab plus corticosteroids. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
| Completed |
NCT05988008 -
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
|
Phase 1 | |
| Active, not recruiting |
NCT02198248 -
Low-dose Glucocorticoid Vasculitis Induction Study
|
Phase 4 | |
| Completed |
NCT06004960 -
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01275287 -
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
|
Phase 2 | |
| Not yet recruiting |
NCT04871191 -
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
|
Phase 2 | |
| Recruiting |
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 | |
| Terminated |
NCT02749292 -
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
|
Phase 4 | |
| Terminated |
NCT02294344 -
The Clinical Efficacy of DFPP in Patients With AAGN
|
N/A | |
| Withdrawn |
NCT01275274 -
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
|
Phase 2 | |
| Completed |
NCT06004947 -
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
|
Phase 1 | |
| Recruiting |
NCT05969522 -
Stratified Therapy on Pediatric AAGN
|
Phase 4 | |
| Recruiting |
NCT03323476 -
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
|
Phase 3 | |
| Completed |
NCT05988021 -
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
|
Phase 1 | |
| Terminated |
NCT01934504 -
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
|
N/A | |
| Recruiting |
NCT06056921 -
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
|
Phase 1 | |
| Not yet recruiting |
NCT02180126 -
Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation
|
N/A | |
| Recruiting |
NCT06294236 -
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
|
Phase 1 | |
| Not yet recruiting |
NCT06379646 -
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
|
N/A |